Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese Adults
NCT01162590 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 52
Last updated 2017-05-19
Summary
The purpose of this study is to assess the safety of Rotarix ™ when administered in healthy adults aged 18 to 45 years in China.
Conditions
- Infections, Rotavirus
Interventions
- BIOLOGICAL
-
Rotarix ™
Oral, single dose
- BIOLOGICAL
-
Oral, single dose
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2010-03-01
- Primary Completion
- 2010-03-31
- Completion
- 2010-03-31
Countries
- China
More Related Trials
-
Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants
NCT00425737 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.
NCT01198769 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks
NCT02914184 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants
NCT00969228 ·Status: COMPLETED ·Phase: PHASE4
-
Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.
NCT00420316 ·Status: COMPLETED ·Phase: PHASE3
-
To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term Infants
NCT00420745 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants
NCT00750893 ·Status: COMPLETED
-
Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in India
NCT00289172 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and Toddlers
NCT05621655 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States
NCT00875641 ·Status: COMPLETED
-
Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized Children
NCT01177826 ·Status: COMPLETED
-
To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines
NCT00140686 ·Status: COMPLETED ·Phase: PHASE3
-
Assessment of Clinical Consistency of Three Production Lots of GSK Biologicals' HRV Vaccine
NCT00757770 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination
NCT00353366 ·Status: COMPLETED
-
Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants
NCT00429481 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.
NCT00432380 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants
NCT00241644 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants
NCT00779779 ·Status: COMPLETED
-
Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months
NCT00385320 ·Status: COMPLETED ·Phase: PHASE2
-
Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian Infants
NCT00938327 ·Status: COMPLETED
-
A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants
NCT00197210 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.
NCT00729001 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants
NCT01616459 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis
NCT00137930 ·Status: COMPLETED ·Phase: PHASE2
-
Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following Administration of Rotarix™
NCT02153333 ·Status: COMPLETED